Literature DB >> 2787123

Open trial of fluoxetine in obsessive-compulsive disorder.

M A Jenike1, L Buttolph, L Baer, J Ricciardi, A Holland.   

Abstract

A 12-week open trial of fluoxetine in 61 obsessive-compulsive disorder patients significantly improved depressive and obsessive-compulsive symptoms. Baseline depression scores were not related to improvement on two obsessive-compulsive scales. The results reinforce the hypothesis of serotonergic abnormalities in obsessive-compulsive disorder.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2787123     DOI： 10.1176/ajp.146.7.909

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


  4 in total

1.  The brain in obsessive-compulsive disorder.

Authors:  P K McGuire
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-11       Impact factor: 10.154

2.  Males and females respond differently to controllability and antidepressant treatment.

Authors:  Benedetta Leuner; Sabrina Mendolia-Loffredo; Tracey J Shors
Journal:  Biol Psychiatry       Date:  2004-12-15       Impact factor: 13.382

Review 3.  Current concepts in the pharmacological treatment of obsessive-compulsive disorder.

Authors:  J Zohar; R C Zohar-Kadouch; S Kindler
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

Review 4.  Obsessive-compulsive disorder in elderly patients.

Authors:  C W Jackson
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.